Arrowhead Directors Sell $1.2M as REDEMPLO Nears EU Vote
Two Arrowhead Pharmaceuticals directors sold a combined $1.19 million in stock on August 18 while shares were gaining 7% on European REDEMPLO regulatory progress, selling into strength rather than red
ARWR Directors Sell $1.2M as Europe Nears Redemplo Vote
NEW YORK, August 24 —
Arrowhead Pharmaceuticals, Inc. (ARWR) sent a contradictory signal last week: as European regulators edged closer to approving REDEMPLO (plozasiran) and shares rallied 7%, two directors sold a combined $1.19 million in stock on August 18. The market is pricing the catalyst. The insiders chose that week to reduce their exposure.
- Directors Perry and Olukotun sold a combined $1.19 million at ~$87 on August 18; no insider purchases in 90 days.
- ARWR rallied 7% the week ending ~August 22 as European regulators neared REDEMPLO approval and analyst optimism rose.
- ARWR holds net cash of ~$220 million; free cash flow is -$49 million on a trailing basis.
The Other Side of the Rally
Director Michael S. Perry sold 11,600 shares at $87.30 for just over $1 million; Director Adeoye Y. Olukotun sold 2,000 shares at $86.96, both on August 18. Both transactions came as ARWR shares were gaining on European regulatory news, selling into strength rather than defensively trimming ahead of a binary risk event. No insider has purchased ARWR shares in the trailing 90-day period, making the net position entirely sell-side. Insider ownership already stood at just 3.7% of shares outstanding before these transactions, so the reduction comes from an already thin base.
The Commercial Inflection
Arrowhead Pharmaceuticals is an RNAi drug developer generating all current revenue ($0.67 billion trailing, up 171% year-over-year) from licensing agreements with GlaxoSmithKline, Takeda, Amgen, and Sarepta rather than commercial sales. REDEMPLO (plozasiran), targeting elevated triglycerides by silencing apolipoprotein C-III production, and Zodasiran, addressing lipid metabolism disorders, are both in Phase 3 trials. European approval of REDEMPLO would mark Arrowhead's first commercial launch, ending the pure-licensing phase (where 100% gross margin is structurally guaranteed) and opening a business with real manufacturing and distribution costs. An FDA priority review voucher could compress U.S. approval to six months, per reporting. Stress-test the commercial-launch scenario with the DCF calculator.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| ARWR | $12.3B | n/a | +320.6% |
| ALNY | $31.6B | 18.8x | -46.8% |
| IONS | $9.9B | n/a | +42.9% |
| AXSM | $10.9B | 41.3x | +78.6% |
| ACAD | $5.1B | 33.2x | +16.5% |
| SRPT | $2.0B | 7.3x | +4.0% |
What Changes the Equation
The consensus analyst price target of $110.18 implies roughly 26.5% upside from the current $87.11, with REDEMPLO's regulatory path as the core input. Arrowhead holds $1.60 billion in cash against $1.38 billion in debt, a net cash position of approximately $220 million, providing runway well beyond the -$49 million free cash flow burn. Two checkpoints define what comes next: the European approval decision on REDEMPLO, and whether the FDA priority review voucher materially compresses U.S. timing. Short interest at 9.5% of float indicates a material bearish position that the regulatory decisions will either vindicate or unwind. Run the free Arrowhead Pharmaceuticals, Inc. deep-dive for current fundamentals as those decisions approach.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Why did Arrowhead Pharmaceuticals directors sell stock?
Directors Michael S. Perry and Adeoye Y. Olukotun sold a combined $1.19 million in shares at approximately $87 on August 18 while the stock was rallying on European REDEMPLO regulatory news. The transactions are characterized as selling into strength rather than defensively trimming ahead of a binary risk event. No insider has purchased ARWR shares in the trailing 90-day period, and insider ownership stood at just 3.7% of shares outstanding before the sales.
What is REDEMPLO and where does approval stand?
REDEMPLO (plozasiran) is Arrowhead's RNAi therapy targeting elevated triglycerides by silencing apolipoprotein C-III production, currently in Phase 3 trials. European regulators were nearing an approval decision as of the week ending approximately August 22, which would mark Arrowhead's first commercial launch. An FDA priority review voucher could compress U.S. approval to six months.
What is the analyst price target for ARWR stock?
The consensus analyst price target is $110.18, implying roughly 26.5% upside from the current share price of $87.11. REDEMPLO's regulatory path is identified as the core input driving that target.
How much cash does Arrowhead Pharmaceuticals hold?
Arrowhead holds $1.60 billion in cash against $1.38 billion in debt, a net cash position of approximately $220 million. Free cash flow was negative $49 million on a trailing basis, and the cash runway extends well beyond the current burn rate.
What is short interest in ARWR?
Short interest stands at 9.5% of float, indicating a material bearish position. The upcoming regulatory decisions on REDEMPLO will either vindicate or unwind that position.
Two Arrowhead Pharmaceuticals directors sold a combined $1.19 million in shares on August 18 — the same week ARWR rallied 7% as European regulators edged closer to approving REDEMPLO (plozasiran). The market is buying the regulatory catalyst; the company's own directors chose that moment to sell.